Relevant bibliographies by topics / Desensitisation / Journal articles

Journal articles on the topic 'Desensitisation'

To see the other types of publications on this topic, follow the link: Desensitisation.
Author: Grafiati
Published: 4 June 2021
Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Desensitisation.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Ramanathan, C., and G. J. Smelt. "Desensitisation." BMJ 302, no. 6778 (March 23, 1991): 726–27. http://dx.doi.org/10.1136/bmj.302.6778.726-c.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Blaszczynski, Alex, and Lia Nower. "Imaginal Desensitisation." Journal of Clinical Activities, Assignments & Handouts in Psychotherapy Practice 2, no. 4 (February 9, 2003): 1–14. http://dx.doi.org/10.1300/j182v02n04_01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Eiser, N. "Desensitisation today." BMJ 300, no. 6737 (June 2, 1990): 1412–13. http://dx.doi.org/10.1136/bmj.300.6737.1412.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ganderton, M. A. "Desensitisation today." BMJ 301, no. 6746 (August 4, 1990): 293. http://dx.doi.org/10.1136/bmj.301.6746.293-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Pottle, A., and M. Barbir. "Statin desensitisation." Atherosclerosis Supplements 28 (September 2017): e11. http://dx.doi.org/10.1016/j.atherosclerosissup.2017.08.020.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Cotrimoxazole desensitisation successful." Reactions Weekly &NA;, no. 653 (May 1997): 4. http://dx.doi.org/10.2165/00128415-199706530-00008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Cotrimoxazole desensitisation successful." Inpharma Weekly &NA;, no. 1089 (May 1997): 21. http://dx.doi.org/10.2165/00128413-199710890-00048.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kelsey, S. M., G. R. Struthers, T. Beswick, and D. R. Blake. "Desensitisation to allopurinol." Annals of the Rheumatic Diseases 46, no. 1 (January 1, 1987): 84. http://dx.doi.org/10.1136/ard.46.1.84.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ridley, M. G., and J. A. Mathews. "Desensitisation to allopurinol." Annals of the Rheumatic Diseases 46, no. 11 (November 1, 1987): 875. http://dx.doi.org/10.1136/ard.46.11.875-a.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Vaughan, K., M. Wiese, R. Gold, and N. Tarrier. "Eye-Movement Desensitisation." British Journal of Psychiatry 164, no. 4 (April 1994): 533–41. http://dx.doi.org/10.1192/bjp.164.4.533.

Full text
Abstract:
A novel approach is described for the treatment of post-traumatic stress disorder (PTSD). Eye-movement desensitisation (EMD) requires the patient to generate images of the trauma in the mind and define physiological and emotional arousal states. While concentrating on these states, lateral multisaccardic eye movements are induced. Ten consecutive cases are reported who presented with symptoms originating from a range of traumas. The effectiveness of EMD in reducing symptoms outlined by DSM–III–R is described. An independent rater indicated that eight of the ten cases showed considerable improvement in PTSD symptoms following EMD, which was maintained at follow-up. Particular reference is given to the ‘specificity’ of EMD in treating symptoms and the changing pattern of effect at follow-up.
APA, Harvard, Vancouver, ISO, and other styles
11

Hamilton, Carlene A., and John L. Reid. "α1-Adrenoceptor desensitisation." European Journal of Pharmacology 152, no. 1-2 (July 1988): 179–83. http://dx.doi.org/10.1016/0014-2999(88)90853-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

&NA;. "Successful desensitisation to zidovudine." Inpharma Weekly &NA;, no. 880 (March 1993): 20–21. http://dx.doi.org/10.2165/00128413-199308800-00051.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

&NA;. "Success with homeopathic desensitisation." Reactions Weekly &NA;, no. 548 (April 1995): 2. http://dx.doi.org/10.2165/00128415-199505480-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

&NA;. "Cotrimoxazole desensitisation was successful." Reactions Weekly &NA;, no. 511 (July 1994): 2. http://dx.doi.org/10.2165/00128415-199405110-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Lanzara, Richard G. "Pharmaceutical Desensitisation Or Fade." Emerging Therapeutic Targets 1, no. 1 (January 1997): 271–73. http://dx.doi.org/10.1517/14728222.1.1.271.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Rodrigues, J., D. Malheiro, C. Botelho, M. C. Cruz, and M. G. Castel-Branco. "Successful desensitisation to Anastrozole." Allergologia et Immunopathologia 37, no. 1 (February 2009): 50–51. http://dx.doi.org/10.1016/s0301-0546(09)70253-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Villanueva Bueno, C., LL Poyatos Ruiz, V. Santana Pareja, E. Montecatine Alonso, MI Sierra Torres, and MD Santos Rubio. "PP-035 Albumin desensitisation." European Journal of Hospital Pharmacy 22, Suppl 1 (March 2015): A130.2—A130. http://dx.doi.org/10.1136/ejhpharm-2015-000639.315.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Snape, S. E., R. G. Finch, and P. Venkatesan. "Aciclovir desensitisation and rechallenge." Case Reports 2011, mar01 1 (March 1, 2011): bcr1020103392. http://dx.doi.org/10.1136/bcr.10.2010.3392.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Rakhit, S., R. Murdoch, and S. M. Wilson. "Persistent desensitisation of the beta 2 adrenoceptors expressed by cultured equine sweat gland epithelial cells." Journal of Experimental Biology 201, no. 2 (January 15, 1998): 259–66. http://dx.doi.org/10.1242/jeb.201.2.259.

Full text
Abstract:
Adrenaline, forskolin and ATP all evoked accumulation of cyclic AMP in equine sweat gland epithelial cells, although the response to adrenaline was more transient than that to forskolin and ATP. Cells preincubated in adrenaline (10 micromol l-1, 32 min) showed essentially complete, homologous desensitisation, and this phenomenon reversed slowly (half-time 6.3+/-0.9 h). After 10 min of recovery from preincubation in adrenaline, isobutylmethylxanthine (IBMX, 5 mmol l-1) had no effect upon the desensitisation and the cells showed no loss of sensitivity to ATP and forskolin. After 10 h, however, the persistent desensitisation was partially reversed by IBMX and the cells showed reduced responses to ATP and forskolin. Increased phosphodiesterase activity may thus contribute to the persistent desensitisation. Experiments using forskolin-preincubated (100 micromol l-1, 32 min) cells suggested that increased cytosolic cyclic AMP levels did not underlie the initial loss of sensitivity to adrenaline but that this second messenger may initiate the series of events leading to the generalised loss of sensitivity seen after 10 h.
APA, Harvard, Vancouver, ISO, and other styles
20

Blaszczynski, Alex, Juliette Drobny, and Zachary Steel. "Home-Based Imaginal Desensitisation in Pathological Gambling: Short-Term Outcomes." Behaviour Change 22, no. 1 (March 1, 2005): 13–21. http://dx.doi.org/10.1375/bech.22.1.13.66782.

Full text
Abstract:
AbstractRandomised controlled outcome studies have demonstrated the efficacy of imaginal desensitisation in inpatient settings. The purpose of this study was to evaluate the effects of a prerecorded audiocassette version of the imaginal desensitisation procedure that was designed for home-based use in reducing gambling urges and behaviours on a sample of diagnosed pathological gamblers who sought treatment at a university teaching hospital at 2-month follow-up. Pretreatment to 2-month follow-up repeated measures revealed a significant reduction in visual analogue scale ratings of urge, preoccupation and perceived self-control over gambling; indices of actual gambling behaviour; and psychometric measures of anxiety, depression and impulsivity. A prerecorded audiocassette version of imaginal desensitisation for home use represents a cost-effective approach in the management of pathological gambling.
APA, Harvard, Vancouver, ISO, and other styles
21

Unavailable, Name. "Case Series on Applications of EMDR to OCD." Advances in Social Sciences Research Journal 8, no. 3 (March 28, 2021): 306–18. http://dx.doi.org/10.14738/assrj.83.9880.

Full text
Abstract:
This paper is an attempt to draw a parallel between the exposure and response prevention (ERP) procedures in CBT (cognitive behaviour therapy) and the desensitisation procedures in EMDR (eye movement desensitisation processing). This paper also suggests an alternative targeting sequence that follows from the standard EMDR protocol to draw upon the strengths and application of ERP procedures in the treatment of OCD (obsessive compulsive disorder).
APA, Harvard, Vancouver, ISO, and other styles
22

Kitchiner, Neil J., Neil Roberts, and Jonathan I. Bisson. "Eye movement desensitisation reprocessing (EMDR)." Mental Health Practice 9, no. 7 (April 2006): 40–44. http://dx.doi.org/10.7748/mhp2006.04.9.7.40.c1908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Bell, EvanT, MichaelL Tapper, and AlanA Pollock. "SULPHADIAZINE DESENSITISATION IN AIDS PATIENTS." Lancet 325, no. 8421 (January 1985): 163. http://dx.doi.org/10.1016/s0140-6736(85)91930-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Watts, D., and J. Bird. "Oxcarbazepine sensitivity treated by desensitisation." Journal of Neurology, Neurosurgery & Psychiatry 54, no. 4 (April 1, 1991): 376. http://dx.doi.org/10.1136/jnnp.54.4.376.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Vischer, T. L., and W. Van Eden. "Oral desensitisation in rheumatoid arthritis." Annals of the Rheumatic Diseases 53, no. 11 (November 1, 1994): 708–10. http://dx.doi.org/10.1136/ard.53.11.708.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

MacCulloch, M. J. "Eye movement desensitisation and reprocessing." Advances in Psychiatric Treatment 5, no. 2 (March 1999): 120–25. http://dx.doi.org/10.1192/apt.5.2.120.

Full text
Abstract:
Eye movement desensitisation and reprocessing (EMDR) was described by Shapiro (1989a,b) as a new method for treating post-traumatic stress disorder (PTSD). In May 1987, while walking in the park, Shapiro noticed that her own disturbing thoughts changed then disappeared “without any conscious effort” (Shapiro, 1995) when they had been temporally paired with diagonal upward to and fro eye movements. Over the next six months Shapiro worked with approximately 70 people to develop a procedure based on the temporal pairing of distressing images and thoughts with various eye movements. Shapiro began to develop strategies to unblock stalled emotional processing, which was initiated by EMDR in non-patients. She successfully tried the method on a Vietnam veteran suffering from severe PTSD and then embarked upon a trial of EMDR on a mixed group of victims of rape, molestation and Vietnam combat trauma. Initially, EMDR achieved wide recognition as a new breakthrough treatment for PTSD. This was, in part, because of very positive early reports (e.g. Wolpe & Abrams, 1991), but also because the EMDR effect appeared to occur with unprecedented speed, often in cases of PTSD that had previously resisted treatment by many other methods over a long period.
APA, Harvard, Vancouver, ISO, and other styles
27

Sangrador-Pelluz, C., M. Martinez-García, MD Pérez-Serrano-Lainosa, R. Olivares-Pallerols, JP Navarro-Ferrando, and E. Soler-Company. "DGI-019 Cisplatin Desensitisation Protocol." European Journal of Hospital Pharmacy 20, Suppl 1 (March 2013): A102.1—A102. http://dx.doi.org/10.1136/ejhpharm-2013-000276.285.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Shadur, Bella, Toby Nicholas Trahair, Tracey O'Brien, Susan Jane Russell, and John Bernard Ziegler. "Desensitisation to liposomal amphotericin B." Journal of Allergy and Clinical Immunology: In Practice 5, no. 1 (January 2017): 181–83. http://dx.doi.org/10.1016/j.jaip.2016.08.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Patriarca, G., A. Buonomo, C. Roncallo, M. Del Ninno, E. Pollastrini, A. Milani, T. De Pasquale, G. Gasbarrini, D. Schiavino, and E. Nucera. "Oral Desensitisation in Cow Milk Allergy: Immunological Findings." International Journal of Immunopathology and Pharmacology 15, no. 1 (January 2002): 53–58. http://dx.doi.org/10.1177/039463200201500107.

Full text
Abstract:
In the literature there are several reports dealing with the possibility of a desensitising treatment in food allergy, but there are very few studies concerning the immunological mechanisms of or al desensitisation. We studied the immunological modifications in four children who underwent oral desensitisation with cow milk. Four children with cow milk allergy underwent oral desensitisation according to a standardized protocol. Total IgE, eosinophilic cationic protein in serum, and specific IgE and IgG4 to α-lactalbumin, to β-lactoglobulin and to casein were determined at the beginning of the treatment and after 6, 12 and 18 months in the 4 children treated. All the 4 treated patients successfully completed the treatment. Specific IgE to casein showed a significant reduction (p<0.01), while specific IgG4 to α-lactalbumin (p<0.02), to β-lactoglobulin (p<0.01) and to casein (p<0.01) showed a significant increase. Total IgE, eosinophilic cationic protein, and specific IgE to a-lactalbumin and to β-Iactoglobulin did not show any significant modification. Control patients did not show any immunological modification and still had a positive double-blind, placebo-controlled food challenge. These results make us think that oral desensitisation in food allergy occurs with the same mechanisms of traditional desensitising treatments for respiratory and insect sting allergies.
APA, Harvard, Vancouver, ISO, and other styles
30

McArdle, CA, J. Franklin, L. Green, and JN Hislop. "Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors." Journal of Endocrinology 173, no. 1 (April 1, 2002): 1–11. http://dx.doi.org/10.1677/joe.0.1730001.

Full text
Abstract:
Sustained stimulation of G-protein-coupled receptors (GPCRs) typically causes receptor desensitisation, which is mediated by phosphorylation, often within the C-terminal tail of the receptor. The consequent binding of beta-arrestin not only prevents the receptor from activating its G protein (causing desensitisation), but can also target it for internalisation via clathrin-coated vesicles and can mediate signalling to proteins regulating endocytosis and mitogen-activated protein kinase (MAPK) cascades. GnRH acts via phospholipase C (PLC)-coupled GPCRs on pituitary gonadotrophs to stimulate a Ca(2+)-mediated increase in gonadotrophin secretion. The type I GnRH receptors (GnRH-Rs), found only in mammals, are unique in that they lack C-terminal tails and apparently do not undergo agonist-induced phosphorylation or bind beta-arrestin; they are therefore resistant to receptor desensitisation and internalise slowly. In contrast, the type II GnRH-Rs, found in numerous vertebrates, possess such tails and show rapid desensitisation and internalisation, with concomitant receptor phosphorylation (within the C-terminal tails) or binding of beta-arrestin, or both. The association with beta-arrestin may also be important for regulation of dynamin, a GTPase that controls separation of endosomes from the plasma membrane. Using recombinant adenovirus to express GnRH-Rs in Hela cells conditionally expressing a dominant negative mutant of dynamin (K44A), we have found that blockade of dynamin-dependent endocytosis inhibits internalisation of type II (xenopus) GnRH-Rs but not type I (human) GnRH-Rs. In these cells, blockade of dynamin-dependent internalisation also inhibited GnRH-R-mediated MAPK activation, but this effect was not receptor specific and therefore not dependent upon dynamin-regulated GnRH-R internalisation. Although type I GnRH-Rs do not desensitise, sustained activation of GnRH-Rs causes desensitisation of gonadotrophin secretion, and we have found that GnRH can cause down-regulation of inositol (1,4,5) trisphosphate receptors and desensitisation of Ca(2+) mobilisation in pituitary cells. The atypical resistance of the GnRH-R to desensitisation may underlie its atypical efficiency at provoking this downstream adaptive response. GnRH-Rs are also expressed in several extrapituitary sites, and these may mediate direct inhibition of proliferation of hormone-dependent cancer cells. Infection with type I GnRH-R-expressing adenovirus facilitated expression of high-affinity, PLC-coupled GnRH-R in mammary and prostate cancer cells, and these mediated pronounced antiproliferative effects of receptor agonists. No such effect was seen in cells transfected with a type II GnRH-R, implying that it is mediated most efficiently by a non-desensitising receptor. Thus it appears that the mammalian GnRH-Rs have undergone a period of rapidly accelerated molecular evolution that is of functional relevance to GnRH-Rs in pituitary and extrapituitary sites.
APA, Harvard, Vancouver, ISO, and other styles
31

Schaff, Mathieu, Nicolas Receveur, Catherine Bourdon, Philippe Ohlmann, François Lanza, Christian Gachet, and Pierre Mangin. "β-arrestin-1 participates in thrombosis and regulates integrin αIIbβ3 signalling without affecting P2Y receptors desensitisation and function." Thrombosis and Haemostasis 107, no. 04 (2012): 735–48. http://dx.doi.org/10.1160/th11-06-0430.

Full text
Abstract:
Summaryβ-arrestin-1 (β-arr1) and β-arrestin-2 (β-arr2) are cytosolic proteins well-known to participate in G protein-coupled receptor desensitisation and signalling. We used genetically-inactivated mice to evaluate the role of β-arr1 or β-arr2 in platelet function, P2Y receptor desensitisation, haemostasis and thrombosis. Platelet aggregation, soluble fibrinogen binding and P-selectin exposure induced by various agonists were near normal in β-arr1−/− and β-arr2−/− platelets. In addition, deficiency in β-arr1 or β-arr2 was not critical for P2Y receptors desensitisation. A functional redundancy between β-arr1 and β-arr2 may explain these unchanged platelet responses. Interestingly, β-arr1−/− but not β-arr2−/− mice were protected against laser- and FeCl3-induced thrombosis. The tail bleeding times, number of rebleeds and volume of blood loss were unchanged in β-arr1−/− and β-arr2−/− mice, suggesting no defect in haemostasis. β-arr1−/− platelet activation upon adhesion to immobilised fibrinogen was inhibited, as attested by a 37 ± 5% (n = 3, p<0.0001) decrease in filopodia extension, suggesting defective signalling through integrin αIIbβ3. β-arr1 appeared to be located downstream of Src family kinases and to regulate αIIbβ3 signalling by increasing Akt phosphorylation. Overall, this study supports a role for β-arr1 in promoting thrombus formation, in part through its participation in αIIbβ3 signalling, and no role of β-arr1 and β-arr2 in agonist-induced platelet activation and P2Y receptors desensitisation.
APA, Harvard, Vancouver, ISO, and other styles
32

Lapner, K. N., C. J. Montpetit, and S. F. Perry. "Desensitisation of chromaffin cell nicotinic receptors does not impede catecholamine secretion during acute hypoxia in rainbow trout (Oncorhynchus mykiss)." Journal of Experimental Biology 203, no. 10 (May 15, 2000): 1589–97. http://dx.doi.org/10.1242/jeb.203.10.1589.

Full text
Abstract:
Experiments were performed on adult rainbow trout (Oncorhynchus mykiss) in vivo using chronically cannulated fish and in situ using a perfused posterior cardinal vein preparation (i) to characterise the desensitisation of chromaffin cell nicotinic receptors and (ii) to assess the ability of fish to secrete catecholamines during acute hypoxia with or without functional nicotinic receptors. Intra-arterial injection of nicotine (6.0×10(−)(7)mol kg(−)(1)) caused a rapid increase in plasma adrenaline and noradrenaline levels; the magnitude of this response was unaffected by an injection of nicotine given 60 min earlier. Evidence for nicotinic receptor desensitisation, however, was provided during continuous intravenous infusion of nicotine (1.3×10(−)(5)mol kg(−)(1)h(−)(1)) in which plasma catecholamine levels increased initially but then returned to baseline levels. To ensure that the decline in circulating catecholamine concentrations during continuous nicotine infusion was not related to changes in storage levels or altered rates of degradation/clearance, in situ posterior cardinal vein preparations were derived from fish previously experiencing 60 min of saline or nicotine infusion. Confirmation of nicotinic receptor desensitisation was provided by demonstrating that the preparations derived from nicotine-infused fish were unresponsive to nicotine (10(−)(5)mol l(−)(1)), yet remained responsive to angiotensin II (500 pmol kg(−)(1)). The in situ experiments demonstrated that desensitisation of the nicotinic receptor occurred within 5 min of receptor stimulation and that resensitisation was established 40 min later. The ability to elevate plasma catecholamine levels during acute hypoxia (40–45 mmHg; 5.3-6.0 kPa) was not impaired in fish experiencing nicotinic receptor desensitisation. Indeed, peak plasma adrenaline levels were significantly higher in the desensitised fish during hypoxia than in controls (263+/−86 versus 69+/−26 nmol l(−)(1); means +/− s.e.m., N=6-9). Thus, the results of the present study demonstrate that activation of preganglionic sympathetic cholinergic nerve fibres and the resultant stimulation of nicotinic receptors is not the sole mechanism for eliciting catecholamine secretion during hypoxia.
APA, Harvard, Vancouver, ISO, and other styles
33

&NA;. "Allopurinol desensitisation protocol: safe and effective." Reactions Weekly &NA;, no. 843 (March 2001): 5. http://dx.doi.org/10.2165/00128415-200108430-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

&NA;. "Desensitisation to PCP prophylaxis in AIDS." Inpharma Weekly &NA;, no. 913 (November 1993): 21. http://dx.doi.org/10.2165/00128413-199309130-00050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

&NA;. "Cotrimoxazole desensitisation has high success rate." Reactions Weekly &NA;, no. 602 (May 1996): 3. http://dx.doi.org/10.2165/00128415-199606020-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Durham, Stephen R. "Allergen immunotherapy (desensitisation) for allergic diseases." Clinical Medicine 6, no. 4 (July 1, 2006): 348–51. http://dx.doi.org/10.7861/clinmedicine.6-4-348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

&NA;. "Desensitisation to PCP prophylaxis in AIDS." Reactions Weekly &NA;, no. 477 (November 1993): 2. http://dx.doi.org/10.2165/00128415-199304770-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

&NA;. "Aspirin desensitisation cost effective for AERD." Inpharma Weekly &NA;, no. 1627 (March 2008): 5. http://dx.doi.org/10.2165/00128413-200816270-00009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

&NA;. "Aspirin desensitisation cost effective for AERD." Reactions Weekly &NA;, no. 1192 (March 2008): 3. http://dx.doi.org/10.2165/00128415-200811920-00005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Cianciulli, P., L. Maffei, F. Sorrentino, L. Morino, and S. Amadori. "Rapid Desensitisation of Desferrioxamine Allergic Reaction." International Journal of Immunopathology and Pharmacology 9, no. 2 (September 1996): 60–61. http://dx.doi.org/10.1177/039463209600900235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Hay, Debbie L., David R. Poyner, and David M. Smith. "Desensitisation of adrenomedullin and CGRP receptors." Regulatory Peptides 112, no. 1-3 (April 2003): 139–45. http://dx.doi.org/10.1016/s0167-0115(03)00032-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Unsworth, J., D. R. Blake, A. E. d'Assis Fonseca, and D. T. Beswick. "Desensitisation to allopurinol: a cautionary tale." Annals of the Rheumatic Diseases 46, no. 8 (August 1, 1987): 646. http://dx.doi.org/10.1136/ard.46.8.646.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

&NA;. "Sulfadiazine desensitisation not recommended in AIDS." Reactions Weekly &NA;, no. 377 (November 1991): 1. http://dx.doi.org/10.2165/00128415-199103770-00001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

van Nunen, S. "Treatment outcomes of rapid desensitisation protocols." Internal Medicine Journal 44, no. 5 (May 2014): 431–33. http://dx.doi.org/10.1111/imj.12412.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Abadoglu, Oznur, Kursat Epozturk, and Emel Atayik. "Rapid oral desensitisation to prophylactic isoniazid." Allergologia et Immunopathologia 39, no. 5 (September 2011): 311–12. http://dx.doi.org/10.1016/j.aller.2010.12.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

McCarthy, C., and R. Conghlan. "Sulphasalazine desensitisation in patients with arthritis." Irish Journal of Medical Science 163, no. 5 (May 1994): 238–39. http://dx.doi.org/10.1007/bf02943259.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Tejasri, B. Prudhvi, R Arunachalam, Kumaresan, and S. Kiruthika. "DESENSITISATION THERAPY IN POST STROKE PAIN SYNDROME: A CASE STUDY." International Journal of Physiotherapy and Research 5, no. 6 (December 11, 2017): 2541–44. http://dx.doi.org/10.16965/ijpr.2017.245.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Page, Andrew C., and Rocco D. Crino. "Eye-Movement Desensitisation: A Simple Treatment for Post-Traumatic Stress Disorder?" Australian & New Zealand Journal of Psychiatry 27, no. 2 (June 1993): 288–93. http://dx.doi.org/10.1080/00048679309075779.

Full text
Abstract:
Eye-movement desensitisation has been identified in a number of case studies to be an effective treatment for post-traumatic stress disorder (PTSD). A further case study reporting success is presented. The treatment appears rapid and may represent a potentially cost-effective treatment for PTSD. However, no treatment study to date has conformed to the ideal methodology of a double-blind placebo controlled trial and therefore its efficacy remains to be demonstrated. A minimal but stringent set of criteria for identification of treatment efficacy are outlined. The implications of eye-movement desensitisation being identified as an effective treatment for PTSD are discussed.
APA, Harvard, Vancouver, ISO, and other styles
49

Başoğlu, Burhan, Mustafa Önder Şekeroğlu, and Emrah Altun. "Relationship between burnout level and socio-democraphic variables of teachers: Ayaş, Güdül, Beypazarı, Nallıhan of sample." Journal of Human Sciences 13, no. 1 (April 10, 2016): 2007. http://dx.doi.org/10.14687/ijhs.v13i1.3763.

Full text
Abstract:
In this study, Maslach Burnout Inventory was used to determine the relationship between 533 teachers’ level of burnout; who work in Ayaş, Güdül, Beypazarı and Nallıhan provinces in the northern of Ankara in different positions and their socio-demographic variables. According to obtained data results; number of children, staff position and felt wealth level in desensitisation dimension and gender, education level and staff position in personal success dimension were determined as significant. It was concluded that marital status, duration of experience in job and staff position in management were not statistically significant on emotional exhaustion, desensitisation and personal success.
APA, Harvard, Vancouver, ISO, and other styles
50

Jeanneton, O., M. Delvaux, Y. Langlois, P. Le Bars, J. Le Bars, M. B. Delisle, J. Frexinos, and L. Bueno. "Correlation of desensitisation of platelet activating factor (PAF) receptors with intensity of inflammation and intestinal PAF content during experimental ileitis in guinea pig." Gut 43, no. 3 (September 1, 1998): 356–64. http://dx.doi.org/10.1136/gut.43.3.356.

Full text
Abstract:
Aim—To determine the kinetics of platelet activating factor (PAF) and prostaglandin E2 (PGE2) receptor desensitisation during intestinal inflammation induced by trinitrobenzenesulphonic acid (TNB) instillation and to study the relation between receptor regulation, inflammatory lesions, and PAF content of the gut wall.Methods—Receptor desensitisation was assessed on isolated smooth muscle cells from the circular layer. PAF content of the intestinal wall was determined by thin layer chromatography and radioimmunoassay.Results—After an acute inflammatory phase on day 1, subacute changes appeared in TNB instilled ileum, with a maximal intensity on day 6. In control animals, PAF 10 nM and PGE2 10 nM provoked a maximal contraction in the range of 24% of cell shortening. On days 1 and 3 after intestinal instillation of TNB, PAF induced contraction was not altered whereas the effect of PGE2 was progressively desensitised (2 logM rightward shift of its concentration-response curve: Cmax = 1 μM; p<0.01). Between days 4 and 6, the concentration-response curve of PGE2 shifted by only 1 logM (p<0.05) whereas the curve of PAF induced contraction shifted by 2 logM (Cmax = 1 μM; p<0.01). The PAF content of the ileal wall was maximal between days 3 and 5 (300 ng/mg tissue). On days 10 and 15, PAF and PGE2 induced contractions were similar to those observed on day 1, and PAF content returned to basal.Conclusion—Inflammation induced by TNB instillation triggers PAF and PGE2 receptor desensitisation; this is dependent on the duration of inflammation and correlates with PAF content in the ileum. This receptor desensitisation may play a protective role by preventing overstimulation of intestinal smooth muscle cells.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Desensitisation' for other source types:
Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography